These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 35224353)

  • 1. Diisothiocyanate-Derived Mercapturic Acids Are a Promising Partner for Combination Therapies in Glioblastoma.
    Xu P; Westhoff MA; Hadzalic A; Debatin KM; Winiarski L; Oleksyszyn J; Wirtz CR; Knippschild U; Burster T
    ACS Omega; 2022 Feb; 7(7):5929-5936. PubMed ID: 35224353
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Viability of glioblastoma stem cells is effectively reduced by diisothiocyanate-derived mercapturic acids.
    Cwiklowska K; Westhoff MA; Freisinger S; Dwucet A; Halatsch ME; Knippschild U; Debatin KM; Schirmbeck R; Winiarski L; Oleksyszyn J; Wirtz CR; Burster T
    Oncol Lett; 2018 Nov; 16(5):6181-6187. PubMed ID: 30344758
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cyclin-dependent kinase inhibitors exert distinct effects on patient-derived 2D and 3D glioblastoma cell culture models.
    Riess C; Koczan D; Schneider B; Linke C; Del Moral K; Classen CF; Maletzki C
    Cell Death Discov; 2021 Mar; 7(1):54. PubMed ID: 33723248
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination therapy in a xenograft model of glioblastoma: enhancement of the antitumor activity of temozolomide by an MDM2 antagonist.
    Wang H; Cai S; Bailey BJ; Reza Saadatzadeh M; Ding J; Tonsing-Carter E; Georgiadis TM; Zachary Gunter T; Long EC; Minto RE; Gordon KR; Sen SE; Cai W; Eitel JA; Waning DL; Bringman LR; Wells CD; Murray ME; Sarkaria JN; Gelbert LM; Jones DR; Cohen-Gadol AA; Mayo LD; Shannon HE; Pollok KE
    J Neurosurg; 2017 Feb; 126(2):446-459. PubMed ID: 27177180
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MicroRNA-21 inhibitor sensitizes human glioblastoma U251 stem cells to chemotherapeutic drug temozolomide.
    Zhang S; Wan Y; Pan T; Gu X; Qian C; Sun G; Sun L; Xiang Y; Wang Z; Shi L
    J Mol Neurosci; 2012 Jun; 47(2):346-56. PubMed ID: 22528454
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Amino acid PET tracers are reliable markers of treatment responses to single-agent or combination therapies including temozolomide, interferon-β, and/or bevacizumab for glioblastoma.
    Ono T; Sasajima T; Doi Y; Oka S; Ono M; Kanagawa M; Baden A; Mizoi K; Shimizu H
    Nucl Med Biol; 2015 Jul; 42(7):598-607. PubMed ID: 25892210
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synergistic Suppression of Glioblastoma Cell Growth by Combined Application of Temozolomide and Dopamine D2 Receptor Antagonists.
    Liu Z; Jiang X; Gao L; Liu X; Li J; Huang X; Zeng T
    World Neurosurg; 2019 Aug; 128():e468-e477. PubMed ID: 31048057
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Synergistic Effect of Combination Progesterone and Temozolomide on Human Glioblastoma Cells.
    Atif F; Patel NR; Yousuf S; Stein DG
    PLoS One; 2015; 10(6):e0131441. PubMed ID: 26110872
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MicroRNA-125b inhibitor sensitizes human primary glioblastoma cells to chemotherapeutic drug temozolomide on invasion.
    Wan Y; Sun G; Zhang S; Wang Z; Shi L
    In Vitro Cell Dev Biol Anim; 2013 Sep; 49(8):599-607. PubMed ID: 23835866
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination therapy with micellarized cyclopamine and temozolomide attenuate glioblastoma growth through Gli1 down-regulation.
    Liu YJ; Ma YC; Zhang WJ; Yang ZZ; Liang DS; Wu ZF; Qi XR
    Oncotarget; 2017 Jun; 8(26):42495-42509. PubMed ID: 28477008
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological inhibition of poly(ADP-ribose) polymerase-1 modulates resistance of human glioblastoma stem cells to temozolomide.
    Tentori L; Ricci-Vitiani L; Muzi A; Ciccarone F; Pelacchi F; Calabrese R; Runci D; Pallini R; Caiafa P; Graziani G
    BMC Cancer; 2014 Mar; 14():151. PubMed ID: 24593254
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cordycepin Augments the Chemosensitivity of Human Glioma Cells to Temozolomide by Activating AMPK and Inhibiting the AKT Signaling Pathway.
    Bi Y; Li H; Yi D; Sun Y; Bai Y; Zhong S; Song Y; Zhao G; Chen Y
    Mol Pharm; 2018 Nov; 15(11):4912-4925. PubMed ID: 30336060
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Temozolomide treatment combined with AZD3463 shows synergistic effect in glioblastoma cells.
    Goker Bagca B; Ozates NP; Asik A; Caglar HO; Gunduz C; Biray Avci C
    Biochem Biophys Res Commun; 2020 Dec; 533(4):1497-1504. PubMed ID: 33109342
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Afatinib and Temozolomide combination inhibits tumorigenesis by targeting EGFRvIII-cMet signaling in glioblastoma cells.
    Vengoji R; Macha MA; Nimmakayala RK; Rachagani S; Siddiqui JA; Mallya K; Gorantla S; Jain M; Ponnusamy MP; Batra SK; Shonka N
    J Exp Clin Cancer Res; 2019 Jun; 38(1):266. PubMed ID: 31215502
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD73 as a target to improve temozolomide chemotherapy effect in glioblastoma preclinical model.
    Azambuja JH; Schuh RS; Michels LR; Gelsleichter NE; Beckenkamp LR; Lenz GS; de Oliveira FH; Wink MR; Stefani MA; Battastini AMO; Teixeira HF; Braganhol E
    Cancer Chemother Pharmacol; 2020 Jun; 85(6):1177-1182. PubMed ID: 32417936
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oncolytic virus-mediated manipulation of DNA damage responses: synergy with chemotherapy in killing glioblastoma stem cells.
    Kanai R; Rabkin SD; Yip S; Sgubin D; Zaupa CM; Hirose Y; Louis DN; Wakimoto H; Martuza RL
    J Natl Cancer Inst; 2012 Jan; 104(1):42-55. PubMed ID: 22173583
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MicroRNA-128-3p Enhances the Chemosensitivity of Temozolomide in Glioblastoma by Targeting c-Met and EMT.
    Zhao C; Guo R; Guan F; Ma S; Li M; Wu J; Liu X; Li H; Yang B
    Sci Rep; 2020 Jun; 10(1):9471. PubMed ID: 32528036
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The interruption of atypical PKC signaling and Temozolomide combination therapy against glioblastoma.
    Dey A; Islam SMA; Patel R; Acevedo-Duncan M
    Cell Signal; 2021 Jan; 77():109819. PubMed ID: 33147518
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhanced Anti-Tumor Activity in Mice with Temozolomide-Resistant Human Glioblastoma Cell Line-Derived Xenograft Using SN-38-Incorporated Polymeric Microparticle.
    Yang TC; Liu SJ; Lo WL; Chen SM; Tang YL; Tseng YY
    Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34074038
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IKBKE enhances TMZ-chemoresistance through upregulation of MGMT expression in glioblastoma.
    Guo G; Sun Y; Hong R; Xiong J; Lu Y; Liu Y; Lu J; Zhang Z; Guo C; Nan Y; Huang Q
    Clin Transl Oncol; 2020 Aug; 22(8):1252-1262. PubMed ID: 31865606
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.